PPPierMarco Piatti

PierMarco Piatti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


PierMarco Piatti has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long lasting protective effects of early l-arginine treatment on endothelium in an in vitro study

    by Elena Galluccio, Serena Spadoni, Barbara Fontana, Emanuele Bosi, Piermarco Piatti, Lucilla D. Monti


  • Open Access

    Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients

    by Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Stefania Salpietro, Nicola Gianotti, Piermarco Piatti, Francesca Cossarini, Concetta Vinci, Elisabetta Carini, Adriano Lazzarin, et al.

    Statin use is associated with a modest increase in the incidence of type 2 diabetes mellitus (DM) among the general population. However, HIV-infected patients have a higher risk of developing DM, and it is unclear whether statins have a diabetogenic effect in these patients. Therefore, we investigated the associations of statin use and exposure to antiretroviral drugs with type 2 DM onset in a cohort of HIV-infected patients. This retrospective, controlled, cohort study identified HIV-1-infected patients who did not have DM and were not receiving statins at their antiretroviral treatment (ART) initiation. Follow-up was accrued from ART initiation to the earliest instance of a DM diagnosis, loss to follow-up, death, or last available visit. The incidence of DM was estimated according to statin use, which was adjusted for periods without statin treatment. The Fine-Gray competing risk model was used in the multivariate analysis to identify risk factors for developing DM. The analyses evaluated 6,195 patients followed for 9.8 years (interquartile range: 4.3–16.3 years). During 64,149 person-years of follow-up (PYFU), 235 patients developed DM (crude incidence: 3.66 [95%CI: 3.20–4.13] per 1,000 PYFU), and 917 (14%) patients used statins. After adjusting for potential confounders, statin use was associated with a non-significant increase in the risk of DM (AHR: 1.21, 95% CI: 0.71–2.07; P = 0.47). DM was more likely among patients who were ever treated with stavudine, and less likely among those ever treated using emtricitabine, tenofovir, abacavir, efavirenz, nevirapine, atazanavir or darunavir. A higher risk of diabetes mellitus was not associated with statin treatment but with traditional risk factors and stavudine use while a reduced risk of DM was associated with the use of emtricitabine, tenofovir, abacavir, efavirenz, nevirapine, atazanavir or darunavir.


  • Smoking is associated with impaired glucose regulation and a decrease in insulin sensitivity and the disposition index in first-degree relatives of type 2 diabetes subjects independently of the presence of metabolic syndrome

    by PierMarco Piatti, Emanuela Setola, Elena Galluccio, Sabrina Costa, Barbara Fontana, Michela Stuccillo, Valentina Crippa, Alberto Cappelletti, Alberto Margonato, Emanuele Bosi, et al.

    The aim of this study was to investigate glucose tolerance, insulin secretion and insulin resistance according to smoking habits in first-degree relatives of type 2 diabetes patients, a population at high risk for developing diabetes. One thousand three hundred (646 females and 654 males) subjects underwent an oral glucose tolerance test (OGTT) to investigate their glucose metabolism and answered questionnaires about their lifestyle habits. Smoker subjects showed significant impairment compared with non-smoker subjects in 2-h post-oral glucose tolerance test (2hOGTT, 129.3 ± 40.2 vs. 117.7 ± 37.6 mg/dl, p < 0.001), the OGTT insulin sensitivity (386.3 ± 54.9 vs. 400.5 ± 53.4 ml min−1 m2, p < 0.01) method and the insulin sensitivity and secretion index-2 (ISSI-2, 1.7 ± 0.8 vs. 2.0 ± 1.0, p < 0.005). Metabolic syndrome (MS) was higher in the smoker than in the non-smoker group (46.5 vs. 29.7 %, p < 0001), and smokers were more sedentary than non-smokers (3.94 ± 3.77 vs. 4.86 ± 4.41 h/week, p < 0.001). Smokers showed an increased risk of impaired glucose regulation (IGR: impaired glucose tolerance or diabetes mellitus) with a hazard ratio (HR) adjusted by gender, metabolic syndrome and physical activity of 1.78, 95 % CI 1.27–2.47 (p < 0.001). The association between smoking and MS conferred a risk of IGR that was five times higher (HR 5.495, 95 % CI 4.07–7.41, p < 0.001). Smoking habit was a significant explanatory variable in a multiple forward stepwise regression analysis performed using 2hOGTT and ISSI-2 as dependent variables (p < 0.0001, R = 0.313 and p < 0.0001, R = 0.347, respectively). In conclusions, our results show that tobacco smoking is tightly associated with impairments in glucose metabolism and insulin sensitivity and insulin secretion.


  • Effect of normalization of fasting glucose by intensified insulin therapy and influence of eNOS polymorphisms on the incidence of restenosis after peripheral angioplasty in patients with type 2 diabetes: a randomized, open-label clinical trial

    by Pier Marco Piatti, Enrico Marone, Manuela Mantero, Emanuela Setola, Elena Galluccio, Pietro Lucotti, Ermal Shehaj, Valentina Villa, Francesca Perticone, Massimo Venturini, et al.

    Primary objective was to evaluate whether an intensified insulin therapy (IIT) incorporating the target of normal fasting glucose and HbA1c levels could halve the incidence of restenosis/amputation/SCA/death at 6 months after peripheral angioplasty compared with standard care (SC) in patients with type 2 diabetes (DMT2) affected by critical limb ischemia (CLI). Forty-six consecutive patients with DMT2 and CLI were randomly assigned to a parallel, open-label study with IIT (basal-bolus glulisine + glargine administrations) or SC (glargine administration + oral antidiabetic drugs). A SNP of eNOS (rs753482-A>C) and circulating CD34+ and CD34+KDR+ progenitor cells were determined. At the end of the study, although HbA1c levels were lower in IIT than in SC (6.9 ± 1.3 % vs. 7.6 ± 1.2 %, p < 0.05), IIT did not reduce the cumulative incidence of restenosis/amputation/SCA/death (52 and 65 %, respectively, odd ratio 0.59; CI 95 %: 0.21–1.62, p = 0.59). rs753482AC+CC as compared with rs753482AA increased the cumulative incidence of restenosis/amputation/SCA/death (79 and 42 %; odd ratio 5.3; CI 95 %: 1.41–19.5, p < 0.02). Baseline CD34+KDR+ were higher in rs753482AA (166.2 ± 154.0 × 106 events) than in rs753482AC+CC (63.1 ± 26.9 × 106 events, p < 0.01). At the end of the study, the highest circulating CD34+KDR+ were found in IIT rs753482AA (246.9 ± 194.0 × 106 events) while the lowest levels were found in SC rs753482AC+CC (70.9 ± 45.0 × 106 events). IIT did not decrease the cumulative incidence of restenosis/amputation/SCA/death in DMT2 and CLI patients. These patients correspond to a class of fragile subjects at high risk of cardiovascular events, and new predictors of restenosis should be contemplated, such as of eNOS polymorphism, (rs753482-A>C SNP) and circulating endothelial progenitor cells.


  • Hypoglycemia and insulin treatment

    by F. Febo, C. Molinari, P. M. Piatti


  • Oral l-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass

    by Pietro Lucotti, Lucilla Monti, Emanuela Setola, Giovanni La Canna, Alessandro Castiglioni, Alessandra Rossodivita, Maria Grazia Pala, Francesco Formica, Giovanni Paolini, Alberico Luigi Catapano, et al.


  • Role of Endothelial Dysfunction and Insulin Resistance in Angina Pectoris and Normal Coronary Angiogram

    by Lucilla Domenica Monti, Pier Marco Piatti

    Angina pectoris and a normal coronary angiogram or cardiac syndrome X is a heterogeneous syndrome that probably encompasses different pathophysiological entities. Patients affected by cardiac syndrome X are often women presenting with severe, invalidating chest pain. However, there is a significant discrepancy among the severity of symptoms, the lack of hemodynamic evidence of myocardial ischemia and the relatively benign long-term prognosis. The vascular endothelium has numerous important functions, including the regulation of vascular tone, blood flow and permeability, secreting both vasorelaxing and vasoconstricting factors. It has been found that both endothelium and non-endothelium-mediated coronary blood flow are impaired in patients with cardiac syndrome X. Interestingly, it has been shown that impaired nitric oxide-dependent vasodilation could increase coronary microvessel tone and produce spasm. It has also been reported that circulating endothelin-1 levels are elevated with a direct relationship between endothelin-1 levels and impaired coronary flow reserve in these patients. In addition, patients with high endothelin-1 levels showed a time onset of chest pain during exercise significantly lower compared to patients with low endothelin-1 concentrations. Moreover, the nitric oxide/endothelin-1 ratio was found decreased in patients with cardiac syndrome X and endothelin-1 levels were also positively correlated with fasting asymmetric dimethylarginine levels. All in all, these data suggest a role of endothelial dysfunction as a cause of regional myocardial and peripheral blood flow abnormalities. Further studies are necessary to characterize the prevailing mechanisms determining alterations in nitric oxide/endothelin-1 pathway in these patients, in order to find new therapies able to improve both quality of life and prognosis. Angina pectoris und ein normales Koronarangiogramm, auch kardiales Syndrom X genannt, umfasst unterschiedlichste pathophysiologische Entitäten. Syndrom-X-Patienten sind häufig Frauen mit schweren, auch die Lebensqualität beeinträchtigenden Symptomen bei Fehlen hämodynamisch nachweisbarer myokardialer Ischämien und relativ guter Langzeitprognose. Das vaskuläre Endothel hat viele wichtige Funktionen. Es regelt den vaskulären Tonus, den Blutfluss und die Permeabilität der Gefäßwand und sezerniert vasorelaxierende und vasokonstringierende Faktoren. Bei Patienten mit Syndrom X ist sowohl die endothelabhängige als auch die nicht endothelabhängige Vasomotion gestört. Interessant ist, dass die Stickstoffmonoxid-(NO-)abhängige Vasodilatation gestört ist und einen erhöhten Tonus der Mikrogefäße hervorrufen kann. Auch koronare Spasmen wurden beobachtet. Das zirkuläre Endothelin-1 ist erhöht und könnte für die eingeschränkte koronare Flussreserve bei diesen Patienten verantwortlich sein. Zusätzlich zeigen Patienten mit hohem Endothelinspiegel einen früher einsetzenden thorakalen Schmerz unter Belastung als Patienten mit niedrigem Endothelinspiegel. Das Verhältnis von NO zu Endothelin-1 ist bei Syndrom-X-Patienten niedrig. Der Endothelin-1-Spiegel korreliert positiv mit dem Nüchternspiegel des asymmetrischen Dimethylarginins. Diese Daten lassen vermuten, dass die endotheliale Dysfunktion eine Ursache für regionale myokardiale und periphere Flussanomalien ist. Weitere Studien sind notwendig, um den Mechanismus zu charakterisieren, der zur Veränderung der NO- und Endothelin-1-Metabolismen bei diesen Patienten führt, um neue therapeutische Ansätze zu finden und die Lebensqualität sowie Prognose der Patienten zu verbessern.